Table 3

 Odds ratios for developing RF and anti-CCP antibodies in the presence of tobacco exposure and/or shared epitope alleles in patients with undifferentiated arthritis

(A) All UA patients at two weeks:
TESEIgM RF+IgM RF−OR95% CIp Value
12551.00
+13481.240.47 to 3.290.63
+19601.454.60 to 3.590.34‡
++18541.530.62 to 3.820.31‡
0.75π
TESEAnti-CCP+Anti-CCP−OR95% CIp Value
6541.00to
+9481.690.49 to 6.190.35
+20473.831.33 to 12.530.01‡
++21474.021.40 to 13.090.01‡
<0.01π
(B) Subgroup of UA patients who develop RA within one year:
TESEIgM RF+IgM RF−OR95% CIp Value
6121.00
+8141.140.26 to 5.240.84
+15221.360.37 to 5.440.61‡
++19132.920.76 to 11.900.08‡
0.87π
TESEAnti-CCP+Anti-CCP−OR95% CIp Value
8101.00
+8130.770.18 to 3.330.69
+19161.480.41 to 5.460.50‡
++2192.920.74 to 11.660.08‡
0.12π
(C) Subgroup of persistent UA patients at one year:
TESEIgM RF+IgM RF−OR95% CIp Value
6371.00
+5320.960.21 to 4.200.95
+9341.630.46 to 6.170.39‡
++4330.750.14 to 3.480.67‡
0.62π
TESEAnti-CCP+Anti-CCP−OR95% CIp Value
‡Comparison TE−/SE+ v TE+/SE+ not significant.
π, p value of χ2 analysis of 2×4 table.
CI, confidence interval; anti-CCP, anti-cyclic-citrullinated peptide; OR, odds ratio; RF, rheumatoid factor; SE, presence of one or two shared epitope alleles; TE, current and past smokers as indicated in the medical history; UA, undifferentiated arthritis.
1361.00
+2342.120.10 to 1280.54
+82710.671.26 to 4860.01‡
++4324.500.41 to 2270.16‡
0.03π